Novartis Sinks 13.5% as Del-Desiran Fails Phase Trial, Putting $12B Avidity Deal Under Scrutiny

The Quick Take

• Novartis shares fell 13.5% after del-desiran, the lead drug in its $12 billion Avidity acquisition, missed its primary endpoint
• The trial failure forces two remaining Avidity pipeline programs to justify the entire $12 billion deal valuation
• Drug trial failures following major acquisitions historically trigger extended re-rating periods for pharma acquirers

Novartis' 13.5% single-day decline reflects the binary risk embedded in large pharma acquisitions where deal economics depend on a lead clinical program advancing successfully. Del-desiran's failure at the primary endpoint invalidates the central thesis behind the $12 billion Avidity purchase, leaving the acquirer to defend a premium price tag on two remaining pipeline assets. Large-cap pharmaceutical M&A is a sector where deal-driven single-day collapses of this magnitude typically signal a multi-quarter re-rating period, as the market reassesses the buyer's capital allocation discipline and the remaining pipeline's standalone valuation worth.

The Novartis selloff creates ripple effects across biotech M&A sentiment: when a high-profile acquirer suffers a major post-acquisition clinical failure, risk premiums on pending pharma deals tend to widen. Other large-cap pharma companies in acquisition discussions face higher investor scrutiny on pipeline risk. Peers in the rare disease and RNA-based therapy space, where Avidity's programs operate, may also see valuation compression as the failed trial raises platform-level efficacy questions. The clinical failure delays Novartis' pipeline diversification objectives by at least 18-24 months, requiring the company to pursue alternative M&A or internal R&D acceleration.

Watch Novartis management's next investor day for guidance on how it will utilize the remaining Avidity programs and whether pipeline pivots are planned. The key trigger is whether the two surviving Avidity assets can generate Phase 2 or Phase 3 data within the next 12 months to partially restore deal confidence. The macro variable is FDA approval rates in rare disease orphan drug categories, which historically run above 60%, making the remaining Avidity programs' survival odds not negligible. Monitor analyst note revisions following the data release, as consensus EPS estimates will likely need material reset to reflect the deal's diminished near-term returns.

Synthesized from 1 source.